Case Report
A Case of Castleman’s Disease during the Long-Term Course of Membranous Nephropathy
Table 1
Laboratory findings on admission.
| Urinalysis | | Specific gravity | 1.019 | Protein | 4+ | Blood | — | Sediment | | Red blood cells | 1–4/HPF | White blood cells | <1/HPF | Urinary biochemical tests | | Daily urinary protein | 6.2 g/24 h | Selectivity index | 0.2 | Bence-Jones protein | Negative | Complete blood count | | White blood cells | 5700/mL | Neutrophils | 45% | Eosinophils | 12% | Basophils | 1% | Lymphocytes | 6% | Monocytes | 36% | Hemoglobin | 9.8 g/dL | Platelets | 23.8 × 104/mL | Blood biochemistry | | Total protein | 6.6 g/dL | Albumin | 1.4 g/dL | Uric acid | 5.3 mg/dL | Urea nitrogen | 10.4 mg/dL | Creatinine | 0.83 mg/dL | Sodium | 138 mmol/L | Chloride | 107 mmol/L | Potassium | 4.0 mmol/L | Corrected calcium | 10.1 mg/dL | Phosphate | 3.5 mg/dL | Blood biochemistry (cont.) | | Total bilirubin | 0.2 mg/dL | Aspartate aminotransferase | 27 U/L | Alanine aminotransferase | 19 U/L | Lactate dehydrogenase | 294 U/L | Alkaline phosphatase | 170 U/L | Creatine kinase | 54 U/L | Total cholesterol | 125 mg/dL | LDL cholesterol | 64 mg/dL | Triglycerides | 102 mg/dL | Glucose | 129 mg/dL | Hemoglobin A1c | 5.9% | Serology | | C-reactive protein | 0.63 mg/dL | HBs antigen | Negative | Anti-HCV antibody | Negative | Immunoglobulin G | 2894 mg/dL | Immunoglobulin A | 450 mg/dL | Immunoglobulin M | 253 mg/dL | Immunoglobulin G4 | 672 mg/dL | Complement 3 (50–98) | 75 mg/dL | Complement 4 (18–49) | 7 mg/dL | CH50 (23–46) | 33.0 U/mL | Antinuclear antibody | <×40 | Cryoglobulin | (−) | Tumor markers, infection | | CEA (0.0–3.4) | 3.2 ng/mL | CA19-9 (0–37) | 44 U/mL | SCC (0.6–2.5) | 3.5 ng/mL | Pro GRP (0–747) | 50.7 pg/mL | sIL-2R (122–496) | 2894 U/mL | T-SPOT | Negative |
|
|
LDL, low-density lipoprotein; HBs, hepatitis B surface; HCV, hepatitis C virus; CH50, 50% hemolytic unit of complement; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; SCC, squamous cell carcinoma; GRP, gastrin releasing peptide; sIL-2R, soluble interleukin-2 receptor; T-SPOT, T cell spot test for tuberculosis; HPF, high-power field.
|